Diagnosis & Treatment

Hull M. et al (2016). CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment

Mathes T. et al. (2014) Factors influencing adherence in Hepatitis-C infected patients: a systematic review. BMC Infectious Diseases, 14:203.

Konerman MA. et al. (2014) Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring–predictors and predictive models of disease progression. Alimentary Pharmacology & Therapeutics, 40(8):863-879.

Kohli A. et al. (2014) Treatment of hepatitis C: a systematic review. JAMA, 312(6):631-640.

Esmat G. et al. (2014) Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues. Liver International, 34(Suppl 1):24-28.

Cheng D. et al. (2014) Peginterferon plus Chinese herbal therapy is associated with a higher virological response than only peginterferon therapy in chronic hepatitis C. European Journal of Clinical Microbiology & Infectious Diseases, 33(3):433-438.

Salk A. et al. (2013) Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature. Annals of Pharmaco

Romero-Gomez M. et al. (2013) Meta-analysis: pegylated interferon alpha-2a achieves higher early virological responses than alpha-2b in chronic hepatitis C. Alimentary Pharmacology & Therapeutics, 37(11):1065-1073.

Redulla R. et al. (2013) Adherence and completion in hepatitis C management: a systematic review. Gastroenterology Nursing, 36(1):53-58.

Rangnekar AS. et al. (2013) IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. Journal of Viral Hepatitis, 20(6):377-384.

Pages